Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05051813 · ClinicalTrials.gov registry record
The Heidelberg Engineering ANTERION Corneal Epithelium Thickness Precision and Agreement Study
A clinical trial, sponsored by Heidelberg Engineering.
- Completed
- Registry status
- 151
- Enrollment target
NCT05051813: Completed study, sponsored by Heidelberg Engineering.
NCT05051813 is a clinical trial that has completed, run by Heidelberg Engineering. The registered enrollment target is 151 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05051813 has completed, sponsored by Heidelberg Engineering.
- COMPLETED
- Registry status
- 151 participants
- Enrollment target
Study Summary
This is a prospective clinical study that will be conducted at one clinical site located in the United States to assess corneal epithelial thickness parameters with the ANTERION
Primary Outcome
Reproducibility, repeatability and agreement of Corneal Epithelial Thickness parameters (0-2mm ring) of ANTERION and the reference device
Interventions
- DEVICE ANTERION
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2021-09-07 |
| Est. Completion | 2024-12-16 |
What the finished NCT05051813 record still lists
NCT05051813 is an observational study that tracks outcomes without assigning an intervention. The registered 151 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which ANTERION is the first listed.
NCT05051813 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05051813 about?
NCT05051813 is a clinical study titled "The Heidelberg Engineering ANTERION Corneal Epithelium Thickness Precision and Agreement Study". This is a prospective clinical study that will be conducted at one clinical site located in the United States to assess corneal epithelial thickness parameters with the ANTERION
What is the current status of trial NCT05051813?
This trial is currently completed. The enrollment target is 151 participants. The study started on 2021-09-07. Estimated completion is 2024-12-16.
What interventions are being tested in trial NCT05051813?
The interventions under investigation include: ANTERION (DEVICE).
Who is sponsoring clinical trial NCT05051813?
This trial is sponsored by Heidelberg Engineering, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01409161 · 151 participants · Phase 2
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- NCT04245397 · 151 participants · Phase 1
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
- NCT05761223 · 151 participants · Phase 1
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
- NCT07195656 · 151 participants · NA
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI